VERV Verve Therapeutics Inc
Price (delayed)
$5.6
Market cap
$473.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.59
Enterprise value
$400.11M
Highlights
VERV's gross profit is up by 29% since the previous quarter
Verve Therapeutics's revenue has increased by 29% from the previous quarter
Verve Therapeutics's equity has increased by 17% YoY but it has decreased by 6% from the previous quarter
The quick ratio has declined by 27% since the previous quarter
VERV's debt is up by 14% since the previous quarter and by 7% year-on-year
Key stats
What are the main financial stats of VERV
Market
Valuations
Earnings
Shares outstanding
84.62M
Market cap
$473.9M
Enterprise value
$400.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.86
Price to sales (P/S)
22.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.38
Revenue
$20.65M
EBIT
-$192.38M
EBITDA
-$179.06M
Free cash flow
-$134.39M
Per share
Balance sheet
Liquidity
EPS
-$2.59
Free cash flow per share
-$1.6
Book value per share
$6.5
Revenue per share
$0.25
TBVPS
$8.32
Total assets
$700.91M
Total liabilities
$154.82M
Debt
$72.48M
Equity
$546.09M
Working capital
$550.52M
Debt to equity
0.13
Current ratio
14.64
Quick ratio
14.46
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
-867.2%
Gross margin
100%
Net margin
-933%
Operating margin
-1,075%
Return on assets
-27.5%
Return on equity
-35.2%
Return on invested capital
-32.8%
Return on capital employed
-29.1%
Return on sales
-931.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VERV stock price
How has the Verve Therapeutics stock price performed over time
Intraday
1.27%
1 week
-16.42%
1 month
-8.2%
1 year
-55.73%
YTD
-59.83%
QTD
14.75%
Financial performance
How have Verve Therapeutics's revenue and profit performed over time
Revenue
$20.65M
Gross profit
$20.65M
Operating income
-$221.97M
Net income
-$192.65M
Gross margin
100%
Net margin
-933%
VERV's net margin has surged by 74% year-on-year and by 24% since the previous quarter
The operating margin has soared by 72% YoY and by 22% from the previous quarter
VERV's gross profit is up by 29% since the previous quarter
Verve Therapeutics's revenue has increased by 29% from the previous quarter
Growth
What is Verve Therapeutics's growth rate over time
Valuation
What is Verve Therapeutics stock price valuation
P/E
N/A
P/B
0.86
P/S
22.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.38
Verve Therapeutics's EPS has increased by 18% YoY and by 10% QoQ
The P/B is 43% below the last 4 quarters average of 1.5
Verve Therapeutics's equity has increased by 17% YoY but it has decreased by 6% from the previous quarter
The price to sales (P/S) is 67% less than the last 4 quarters average of 68.7
Verve Therapeutics's revenue has increased by 29% from the previous quarter
Efficiency
How efficient is Verve Therapeutics business performance
Verve Therapeutics's return on sales has surged by 74% YoY and by 24% QoQ
VERV's return on invested capital is up by 8% year-on-year and by 3.8% since the previous quarter
The ROA has grown by 8% YoY and by 6% from the previous quarter
VERV's ROE is up by 6% QoQ and by 5% YoY
Dividends
What is VERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VERV.
Financial health
How did Verve Therapeutics financials performed over time
The quick ratio has declined by 27% since the previous quarter
The current ratio has declined by 26% since the previous quarter but it is up by 2.2% year-on-year
VERV's debt is 87% smaller than its equity
VERV's debt to equity is up by 18% since the previous quarter but it is down by 13% year-on-year
Verve Therapeutics's equity has increased by 17% YoY but it has decreased by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.